Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study
Gayathri Nagaraj(Loma Linda University), Gary H. Lyman(University of Washington), Chris Labaki(Beth Israel Deaconess Medical Center), Jared D. Acoba(University of Hawaiʻi at Mānoa), Ali Raza Khaki(Palo Alto Institute), Daniel Flora(St. Elizabeth Healthcare), Shilpa Gupta(Cleveland Clinic), Matthew D. Galsky(Icahn School of Medicine at Mount Sinai), Hala T. Borno(San Francisco Public Library), Horyun Choi(University of Hawaiʻi at Mānoa), Petros Grivas(Seattle Cancer Care Alliance), Cecilia A. Castellano(Emory University), Monika Joshi(Pennsylvania State University), Ziad Bakouny(Dana-Farber Cancer Institute), John F. Deeken(Inova Health System), Vadim S. Koshkin(UCSF Helen Diller Family Comprehensive Cancer Center), Chinmay Jani(Mount Auburn Hospital), Nicole Balmaceda(The University of Texas MD Anderson Cancer Center), Mark A. Lewis(Emory University), Joy Awosika(University of Cincinnati), Nicole M. Kuderer, Natasha Edwin(Washington University in St. Louis), Hannah Heilman(University of Cincinnati), Cyndi J Gonzalez(University of Michigan), Marcy Haynam(The Ohio State University), Clara Hwang(Henry Ford Health System), Virginia Kaklamani(Northwestern University), Mehmet Asım Bilen(Emory Healthcare), Ting Bao(Hubei University), Elizabeth J. Klein(Brown University), David M. Aboulafia(Virginia Mason Medical Center), Christopher R. Friese(University of Michigan), Sibel Blau(University of Washington Tacoma), Babar Bashir(Thomas Jefferson University), Stephanie Berg(Loyola University Medical Center), Brianne E Bodin(Columbia University Irving Medical Center), Daniel H. Kwon(Harvard University), Philip E. Lammers, Aakash Desai(University of Connecticut), Xuanyi Li(Vanderbilt University), Natalie Knox(Public Health Agency of Canada), Lawrence Feldman(University of Illinois Chicago), Dawn L. Hershman(Columbia University), Tianyi Sun(Vanderbilt University Medical Center), Poorva Bindal(Beth Israel Deaconess Medical Center), Shaveta Vinayak(Roswell Park Comprehensive Cancer Center), Gilbert de Lima Lopes(University of Miami), Kate Lathrop(The University of Texas MD Anderson Cancer Center), Amit Kulkarni(University of Minnesota)
Cited by 3
Related Papers
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k